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Introduction
Infantile onset epileptic encephalopathies often present with
intractable seizures, cognitive, behavioral, and neurological def-
icits and usually have a poor prognosis. The number of mono-
genic disorders that cause epileptic encephalopathies and the
phenotypic spectrum of diverse monogenic epilepsies are rap-
idly expanding. Driven by a candidate gene approach an increas-
ing number of channelopathies has been related to genetic
epilepsies. Voltage-gated sodium channels initiate action poten-
tials in nerve, muscle, and other excitable cells and are essential
for normal neuronal ﬁring. Mutations in the various voltage-
gated sodiumchannels cause a broad spectrumofdisorderswith
predominant paroxysmal features such as epilepsy, hemiplegic
migraine, periodic paralysis, or cardiac conduction defects.Well-
knownphenotypes associatedwithmutations in theSCN1Agene
may lead to severe myoclonic epilepsy of infancy and genetic
epilepsy with febrile seizures plus. Mutations in the SCN2A gene
wereoriginally describedwithbenign familial-neonatal infantile
seizures (BFNIS).1 Over recent years, the spectrum of SCN2A
mutations has widened markedly2,3 with descriptions of some
severely affected patients. We report on a girl with a de novo
SCN2A mutation presenting with intractable seizures, primary
global developmental impairment, and additional features such
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Abstract Mutations of the SCN2A gene have originally been described in association with benign
familial neonatal-infantile seizures (BFNIS). Recently, single patients with more severe
phenotypes and persisting epileptic encephalopathies have been recognized. We report
the case of a girl with severe infantile onset epileptic encephalopathy and a de novo
missensemutation in the SCN2A gene (c.4025T > C/ ¼ ; p.L1342P/ ¼ ), who presented
with a transient choreatic movement disorder, hypersomnia, and progressive brain
atrophy. Whole exome sequencing did not reveal any other disease causing mutation.
Our patient contributes to the expanding phenotypic spectrum of SCN2A-related
disorders and underlines the importance of genetic workup in epileptic
encephalopathies.
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as choreoathetotic movements, hypersomnia, and progressive
brain atrophy.
Case Report
The girl is the ﬁrst child of a healthy Japanese mother and a
European father who had benign focal childhood epilepsy
with centrotemporal spikes. The patient was delivered by
caesarean section after an uneventful pregnancy. Her Apgar
scores were 7/9/10, head circumference was 36 cm (percen-
tile: 50–75), body length 48 cm (percentile: 3), weight 2,970 g
(percentile: 3–10); physical appearance was normal. Early
development was remarkable due to feeding problems, rare
smiling, and lack of visual contact. At the age of 5 months, she
was referred to our neuropediatric outpatient clinic by an
ophthalmologist, who suspected infantile spasms because of
abnormal eye movements. The girl presented with severe
truncal hypotonia, choreoathetotic movements predomi-
nantly of the upper extremities and the face. Electroenceph-
alography (EEG) revealed hypsarrhythmia accentuated over
the left hemisphere and short bursts of β rhythms. Short tonic
seizures occurred with brisk stretching of the right arm,
ﬂexion of the left arm, gaze deviation to the left, and
narrowing of the left palpebral ﬁssure, occasionally associat-
ed with a facial ﬂush (►Video 1). Ictal EEG showed pro-
nounced slowing, amplitude suppression over the right
hemisphere, and multifocal sharp wave activity. Pyridoxine
was ineffective but seizures were initially controlled by
vigabatrin. Because of persisting hypsarrhythmia predniso-
lone (4  10 mg) was administered over 4 weeks and lead to
resolution of hypsarrhythmia. Hypsarrhythmia and seizures
relapsed 4 weeks after steroid withdrawal and since then
seizures remained therapy resistant to topiramate, lamotri-
gine, phenobarbital, valproic acid, levetiracetam, clobazam,
sultiame, and a 2.5:1 ketogenic diet. At the age of 1 year and
9months, tonic seizureswere associatedwith left hemispheric
rhythmic theta activity and simultaneous right hemispheric
rhythmic sharp waves followed by suppression on EEG
(►Fig. 1). Over the years, different seizure types evolved,
mainly generalized and focal tonic seizures as well as serial
myoclonic jerks. Head circumference dropped below the third
percentile by the age of 6 months. During infancy, the mother
reported prolonged sleeping up to 22 hours per day indepen-
dent of the anticonvulsive drugs administered and the child
had to be awakened for regular feeds. In polysomnography
sleep cycles were poorly depicted and hypersomnia could not
be quantiﬁed due to continuous predominant delta activity
and absent spindles and K-complexes. The choreoathetotic
movements decreased from the age of 12months, but daytime
sleepiness persisted. At the age of 4 years, her head circumfer-
ence was 46 cm, 4.0 standard deviation scores; length and
weight were on the third percentile. She was still having
approximately 10 seizures per day. Visual contact was absent,
spontaneous movements were rare and undirected; she had
profound hypotonia with head lag and brisk reﬂexes with an
exhaustible ankle clonus.
Video 1
Choreoathetotic movements and short tonic seizure.
Online content including video sequences viewable at:
https://www.thieme-connect.com/products/
ejournals/html/10.1055/s-0034-1372302.
Cranial magnetic resonance imaging at age 5 months and
2.5 years revealed a progressive cortical and subcortical
atrophy and a minor cerebellar atrophy. Proton magnetic
resonance spectroscopy of the basal ganglia andwhitematter
showed normal metabolites. Extended metabolic workup
revealed normal plasma amino acids, acylcarnitines, sialo-
transferrin isoelectric focusing, pipecolic acid, homocysteine,
Fig. 1 Focal seizure pattern (electroencephalography) at the age of 1 year and 9 months. Evolution of rhythmic left hemispheric theta activity,
meanwhile rhythmic sharp over the right temporo-occipital region followed by generalized suppression.
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and guanidinoacetate. CSF lactate, biogenic amines, folate,
pterins, and amino acids, as well as the CSF to blood glucose
ratio were all normal, as were organic acids in urine. The
karyotype was 46,XX; high-resolution chromosomal micro-
array analysis using an Affymetrix cytogenetics 2.7 array
revealed only common copy number polymorphisms. At
the age of 4 years, targeted Sanger sequencing of the SCN2A
gene was performed because it was recently found to repre-
sent one of the most common causes of unexplained severe
intellectual disability4 and lead to the detection of a hetero-
zygous missense mutation (c.4025T > C/ ¼ ; p.L1342P/ ¼ ),
which was absent in both parents. Pathogenicity of this
mutation is supported by its de novo occurrence, exchange
of a highly conserved amino acid, and mutation modeling.
Transmembrane helices in SCN2A were predicted using the
programs TmHMM,5 TMpred, and Toppred.6 The topology of
the transmembrane helix and the effect of the mutationwere
modeled with Sybyl7 (Tripos Inc., St Louis, Missouri, United
States). RASMOL7 was used for visualization. All three tools
independently predict that L1342 is located in a transmem-
brane helix of SCN2A. These methods additionally list scores,
which are a measure for the helix forming propensity of the
respective sequence stretch. As indicated by the scores, a
replacement of L1342 by proline decreases the helix propen-
sity suggesting that the helix is less stable in the mutant
(►Fig. 2). A deleterious or damaging effect was also highly
supported by PolyPhen2 (1.0000), SIFT (D), LRT (0.0003),
MutationTaster (0.9956), MutationAssessor (5.02), and
PhyloP (1.78) in silico analysis. The c.4025T > C mutation
was previously unreported including the data from the 1,000
genome project and the 6,500 exomes of the National Heart,
Lung, and Blood Institute. Considering the possibility of an
independent, nonallelic second mutation as a modiﬁer of the
phenotype, we performed whole exome sequencing of the
patient and both parents using a SOLID 5500 XL device
(Carlsbad, California, United States) and the Agilent Sure-
Select Human All Exon V5 capturing system (Agilent, Santa
Clara, California, United States) with a 65 forward/30 reverse
read length and an average read depth of 146 . Trio data
were analyzed for de novo and homozygous or compound
heterozygous rare variants. In addition to the previously
identiﬁed SCN2A mutation, three additional de novo hetero-
zygousmutations were observed, all of whichwere predicted
to be benign by the various in silico tools and occurred in
genes with no known disease association (FAM75A4 c.676G
> A, p.D226N; TMEM55B c.289C > T, p.L97F; SLFN11 c.1691T
> A, p.L564H). Likewise, compound heterozygous variants in
the genes ANKRD35 and TRIML2with unknown function and
in the OTOG gene causing autosomal recessive nonsyndromic
hearing loss were predicted to be benign. Only the compound
heterozygous variants (rs139476696—minor allel frequency
of 0.0005 — and rs144054131 — minor allel frequency of
0.0023) identiﬁed in the PPARGC1B gene reached a medium
score of pathogenicity, but neither a disease association with
these speciﬁc SNPs nor an autosomal recessive disease has yet
been assigned to the encoded peroxisome proliferator-activated
receptor gamma, co-activator 1β (also known as ERRL1, PERC,
PGC-1(β), and PGC1B). After detection of the mutation, carba-
mazepine was introduced leading to a signiﬁcant increase in
seizure frequencyand therefore discontinuation after a fewdays.
Discussion
Mutations of the sodium channel subunit gene SCN2A have
initially been described in several families with BFNIS.1 BFNIS
is characterized by suddenneonatal infantile onset of seizures
with remission in infancy and normal development. In recent
years, the clinical spectrumof SCN2Amutations has expanded
considerably. Our patient presented with marked develop-
mental delay before the detection of hypsarrhythmia and the
onset of tonic seizures at the age of 5 months. Over time,
seizure patterns became more variable and remained phar-
macoresistant as described in other patients with the severe
phenotype of SCN2A-related encephalopathy. Our patient
showed some additional distinct features. Notably, the con-
tinuous choreatic movements were impressive during infancy
and preceded the onset of epilepsy. Chorea and ballism
associated with infantile spasms, severe developmental delay,
and cerebral atrophy have yet been described in one girl with a
de novo SCN2A mutation.2 Interestingly, hypermotoric move-
ment disorders can occur along other infantile epilepsies as
choreo–ballistic movements associated with guanidionoace-
tate methyltransferase deﬁciency8 and STXBP1 mutations9 or
paroxysmal kinesigenic dyskinesia with PRRT2-related infan-
tile convulsions.10 While choreatic movements in PRRT2 are
described as paroxysmal our patient had constant choreoa-
thetotic movements that were only interrupted by sleep but
subsided beyond infancy without speciﬁc treatment.
Hypersomnia has so far not been reported in cases with
SCN2A mutations. Though excessive daytime sleep was evi-
dent in our patient, this could not be proven by polysomnog-
raphy as sleep-speciﬁc patterns were absent. Voltage-gated
Fig. 2 Structure of residues 1,336 (blue tube) to 1,349 (orange tube)
of the SCN2A transmembrane helix. The wild type and L1342P mutant
are shown in the left and right panel, respectively. Residues 1,338,
1,342, and 1,346 are shown in stick presentation and backbone
hydrogen bonds are indicated as black dotted lines. Because of the lack
of an amide proton, P1342 cannot form a hydrogen bond with M1338,
which is predicted to lead to a destabilization of the helix and a
rearrangement of M1338 (magenta arrow). In addition, the bulky ring
of the proline causes a rearrangement of the M1338 backbone
suggesting that the mutation affects both the stability and geometry
of the transmembrane helix.
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sodium channels seem to play an important role in sleep
homeostasis as demonstrated in mouse models in SCN1A and
SCN8A mutations. The mutant mice developed altered sleep
regulation with sleep deﬁcit in SCN1A and reduced wakeful-
ness in SCN8A mutations.11 Cerebral atrophy, as observed in
our patient, has been reported in severe cases of epileptic
encephalopathies including SCN1A and SCN2A mutations.2
Almost all SCN2Amutations are missense as in our patient.
Functional consequences range from gain-to-loss-of-function
of the Nav1.2 channel. Thus, characterization of the impact of
individual mutations on channel function could well inﬂuence
the choice of anticonvulsant drugs. In general, it seems that
channel properties are altered to a greater extent in patients
with intractable epilepsies.3 The p.L1342P mutation observed
in our patient affects one of the six transmembrane segments
of domain III of the Nav1.2 channel and is predicted to result in
destabilization of the protein. We tried carbamazepine in our
patient because many reported SCN2A mutations result in a
gain of function of the Nav1.2 channel. Unfortunately, we saw
an increase in seizure frequency so it can be hypothesized that
her mutation rather leads to a loss of function.
In a recent study, SCN2A missense mutations were de-
tected in 15 of 328 patients with early onset epileptic
encephalopathies.2 Nine of the described cases were classi-
ﬁed as Ohtahara syndrome.
Another study identiﬁed mutations in the SCN2A gene as
one of the most common causes of unexplained, isolated
severe intellectual disability by whole exome sequencing.4
This questions the selective impact of epileptiform activity on
the cognitive abilities of children with SCN2A mutations and
the deﬁnition of epileptic encephalopathy per se.
In our patient, the co-occurrence of severe global develop-
mental impairment, intractable epilepsy, and a transient
movement disorder led to the suspicion of a monogenic
disorder and to sequencing of the SCN2A gene as the ﬁrst of
several possible candidate genes.
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